We initially investigated presence of CD169+ macrophages in the paired LNM/UnLN samples with the help of IHC and QuPath, to confirm previous knowledge regarding regression of CD169+ macrophages in involved lymph nodes from cancer patients [16, 21, 23, 29, 35, 36], but also to investigate their location as being SCS CD169+ macrophages or MS CD169+ macrophages. This evidence concerns the gene SIGLEC1 and cancer.